JACOBIO-B News

JACOBIO-B: VOLUNTARY ANNOUNCEMENTJACOBIO PRESENTED THE PRELIMINARY CLINICAL DATA OF BETINHIBITOR JAB-8263 TO TREAT MYELOFIBROSIS AT THE 2024 66THAMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING

Dec 8 18:50 ET

JACOBIO-B: Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 November 2024

Dec 3 03:40 ET

JACOBIO-B: VOLUNTARY ANNOUNCEMENT JACOBIO COMPLETED FIRST PATIENT DOSAGE IN THE PHASE I/IIa CLINICAL TRIAL OF PAN-KRAS INHIBITOR JAB-23E73 IN CHINA

Nov 24 19:07 ET

JACOBIO-B: Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 October 2024

Nov 4 05:44 ET

JACOBIO-B: NEXT DAY DISCLOSURE RETURN

Oct 25 05:13 ET

JACOBIO-B: NEXT DAY DISCLOSURE RETURN

Oct 21 05:59 ET

JACOBIO-B: VOLUNTARY ANNOUNCEMENTGLECIRASIB FOR THE TREATMENT OF PANCREATIC CANCER HASBEEN GRANTED ORPHAN DRUG DESIGNATION IN EUROPE

Oct 20 20:13 ET

JACOBIO-B: NEXT DAY DISCLOSURE RETURN

Oct 18 08:25 ET

JACOBIO-B: NEXT DAY DISCLOSURE RETURN

Oct 9 07:13 ET

JACOBIO-B: VOLUNTARY ANNOUNCEMENTJACOBIO PRESENTED THE PRE-CLINICAL DATA OF SHP2 INHIBITORJAB-3312 IN COMBINATION WITH KRAS G12C INHIBITOR GLECIRASIBAT THE FIFTH RAS INITIATIVE SYMPOSIUM 2024

Oct 8 19:55 ET

JACOBIO-B: NEXT DAY DISCLOSURE RETURN

Oct 8 07:34 ET

JACOBIO-B: Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2024

Oct 7 04:43 ET

JACOBIO-B: VOLUNTARY ANNOUNCEMENTJACOBIO TO PRESENT THE CLINICAL DATA OF BET INHIBITORJAB-8263 AT THE 2024 66TH AMERICAN SOCIETY OF HEMATOLOGYANNUAL MEETING

Oct 2 18:02 ET

JACOBIO-B: VOLUNTARY ANNOUNCEMENTJACOBIO RECEIVED UPFRONT PAYMENT UPON THE ENTRY INTOEXCLUSIVE LICENSING-OUT AGREEMENT FOR GLECIRASIB AND JAB-3312 WITH ALLIST

Sep 26 18:15 ET

JACOBIO-B: VOLUNTARY ANNOUNCEMENTJACOBIO RECEIVED CHINA CDE INVESTIGATIONALNEW DRUG CLEARANCE FOR PAN-KRAS INHIBITOR JAB-23E73

Sep 26 00:08 ET

JACOBIO-B: VOLUNTARY ANNOUNCEMENT JACOBIO RECEIVED INVESTIGATIONAL NEW DRUG (IND) APPROVAL FROM THE U.S. FDA FOR PAN-KRAS INHIBITOR JAB-23E73

Sep 22 19:39 ET

JACOBIO-B: Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 August 2024

Sep 3 04:33 ET

JACOBIO-B: LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS

Aug 30 07:02 ET

JACOBIO-B: INSIDE INFORMATION - JACOBIO ANNOUNCES EXCLUSIVE LICENSING-OUT AGREEMENT WITH ALLIST FOR GLECIRASIB AND JAB-3312

Aug 30 04:44 ET

JACOBIO-B: VOLUNTARY ANNOUNCEMENT JACOBIO COMPLETED FIRST PATIENT DOSAGE IN THE PHASE III CLINICAL TRIAL OF JAB-3312 IN COMBINATION WITH GLECIRASIB

Aug 7 04:39 ET